Blood CirculationNCT07643532
A Single-center, Randomized, Double-blind, Placebo-controlled, Intervention Clinical Trial to Evaluate the Efficacy and Safety of "KoreaGinseng F Max" on Blood Circulation Improvement in Adults With Poor Peripheral Blood Flow
A study testing KoreaGinseng F Max in people with Blood Circulation and Peripheral Blood Flow, run by Haiphong University of Medicine and Pharmacy at 1 site in Vietnam.
Trial summary
This is a single-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a white ginseng extract (KoreaGinseng F Max) for improving blood circulation in adults with poor peripheral blood flow. Read more about this study
- Who is it for?
- Ages 20 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Blood Circulation, Peripheral Blood Flow, Platelet Aggregation
- What is being tested?
- KoreaGinseng F Max
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteVietnam
- Study dates
- 10 Jun 2026to 10 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Men or women aged 20 to under 65 years
- Platelet aggregation response above 55% (satisfied for both collagen and ADP)
- Provides voluntary written informed consent to participate
Who cannot join
- History of hypersensitivity or allergy to ginseng-containing products that may affect the results
- Surgery under general anesthesia within 12 weeks before participation
- Use of contraindicated products such as red ginseng or omega-3 fatty acids within 2 weeks before screening
- Use of antiplatelet drugs such as aspirin within 2 weeks before screening (subjects on prophylactic aspirin <100 mg with unchanged dose/method may participate)
- Uncontrolled hypertension not managed by medication (systolic BP >160 mmHg or diastolic BP >97 mmHg)
- Currently using study-indicated medications such as those for dyslipidemia or diabetes
Show all 21Show fewer
- On drug treatment with a history of peripheral atherosclerosis and coronary artery disease (peripheral vascular disease, abdominal aortic aneurysm, carotid artery disease)
- Coronary artery bypass surgery, vascular anastomosis, pacemaker use, myocardial infarction, heart failure, arrhythmia, or other cardiac disease within 6 months
- Infectious inflammatory disease, systemic infection, immune-resistance-related disease, or leukemia (blood cancer)
- Irritable bowel syndrome, gastrointestinal resection surgery, or GI-related disease such as Crohn's disease
- History of cerebral ischemia or cerebral hemorrhage such as cerebral infarction or stroke due to atherosclerosis
- Concurrent symptoms of myocardial infarction, atherosclerosis, or congestive heart failure
- Clinically significant liver dysfunction (ALT or AST ≥2.5x the upper limit of normal)
- Clinically significant renal dysfunction (serum creatinine >2.0 mg/dL)
- TSH outside 0.27-5.07 microIU/mL or thyroid disease
- History of, or current treatment for, psychiatric/neurological disorders including schizophrenia, depression, or drug addiction
- History of malignant tumor within 5 years before screening
- Pregnant or breastfeeding women, women of childbearing potential not using medically reliable contraception, or women within 6 months postpartum
- Alcohol consumption within the last 3 days (men 30 g/day, women 20 g/day)
- Participation in another clinical trial within 4 weeks before participation
- Subjects judged unsuitable by the investigator or other physicians
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Vietnam1 site
Hai Phong University of Medicine and Pharmacy
Haiphong, Hải Phòng, 180000
Tran Van Anh, Master, +84 343035492, tvanh@hpmu.edu.vn
About this study
This is a single-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a white ginseng extract (KoreaGinseng F Max) for improving blood circulation in adults with poor peripheral blood flow.
A total of 100 adults aged 20 to under 65 years with platelet aggregation above 55% will be enrolled and randomly assigned in a 1:1 ratio to receive either the white ginseng extract or a matching placebo for 8 weeks. Each participant takes 3 tablets after breakfast and 3 tablets after dinner (6 tablets per day).
The main goal is to measure the change in ADP-induced platelet aggregation from baseline (Visit 2) to the end of treatment (Visit 4, Week 8). The study also assesses effects on coagulation measures, blood lipids, serotonin, blood pressure, white blood cell count, and overall safety.
Read the detailed description
Study design: Single-center, randomized, double-blind, placebo-controlled, parallel-group interventional trial.
Population: Men or women aged ≥20 and <65 years requiring improvement of blood circulation, with ADP- and collagen-induced platelet aggregation above 55%, who provide written informed consent.
Intervention: Participants are randomized 1:1 to the test product (white ginseng extract, KoreaGinseng F Max) or a matching placebo control. Dosing is 3 tablets after breakfast and 3 tablets after dinner (6 tablets/day) for 8 weeks, taken orally.
Visit schedule: Screening (Visit 1, Week -2 to 0); randomization/baseline (Visit 2, Week 0); interim visit (Visit 3, Week 4 ±5 days); end-of-treatment (Visit 4, Week 8 ±5 days); plus a supplementary visit if needed.
Primary endpoint: Change in ADP-induced platelet aggregation from baseline (Visit 2) to Visit 4.
Secondary endpoints: Percent change in ADP-induced platelet aggregation; change and percent change in prothrombin time and activated partial thromboplastin time; change in serum lipids (total cholesterol, HDL-C, LDL-C, triglycerides); change in serotonin; change in systolic and diastolic blood pressure; and - all from baseline to Visit 4.
Sample size: 100 participants (2 groups); approximately 50 evaluable per group, accounting for an ~8% dropout rate.
- Being tested
- KoreaGinseng F Max, Placebo
- Keywords
- White ginseng extract, KoreaGinseng F Max, Platelet aggregation, Blood circulation, Antiplatelet, Dietary supplement, Functional food
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
KoreaGinseng F MaxDietary supplement
White ginseng extract; 3 tablets after breakfast and 3 tablets after dinner (6 tablets/day), oral, for 8 weeks.
PlaceboDietary supplement
Matching placebo control product; same dosing schedule and duration as the test product.
| Study group | Role | What they receive |
|---|---|---|
| White Ginseng Extract (KoreaGinseng F Max) | Experimental | Participants receive white ginseng extract (KoreaGinseng F Max), 3 tablets after breakfast and 3 tablets after dinner (6 tablets/day) orally for 8 weeks. Receives: Dietary Supplement: KoreaGinseng F Max |
| placebo | Placebo comparator | Participants receive a matching placebo control product on the same dosing schedule (3 tablets after breakfast and 3 tablets after dinner, 6 tablets/day) orally for 8 weeks. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in ADP-induced platelet aggregation
Change in adenosine diphosphate (ADP)-induced platelet aggregation from baseline to end of treatment.
Measured: Baseline (Visit 2) and Week 8 (Visit 4)
Secondary outcomes (6)
Percent change in ADP-induced platelet aggregation
from baseline to end of treatment
Measured: Baseline (Visit 2) and Week 8 (Visit 4)
Change and percent change in prothrombin time (PT)
from baseline to end of treatment
Measured: Baseline (Visit 2) and Week 8 (Visit 4)
Change and percent change in activated partial thromboplastin time (aPTT)
from baseline to end of treatment
Measured: Baseline (Visit 2) and Week 8 (Visit 4)
Change and percent change in serum lipids (total cholesterol, HDL-C, LDL-C, triglycerides)
from baseline to end of treatment
Measured: Baseline (Visit 2) and Week 8 (Visit 4)
Change and percent change in serum serotonin
from baseline to end of treatment
Measured: Baseline (Visit 2) and Week 8 (Visit 4)
Change and percent change in blood pressure (systolic and diastolic)
from baseline to end of treatment
Measured: Baseline (Visit 2) and Week 8 (Visit 4)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2026
- Study start10 Jun 2026 (estimated)
- Primary completion10 Dec 2026 (estimated)
- Study completion10 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood CirculationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Two parallel groups randomized 1:1 to white ginseng extract or matching placebo.
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Haiphong University of Medicine and Pharmacy
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07643532
- Sponsor's protocol ID
- NIHHS-24-01
- Status last verified
- Jun 2026
- First submitted
- 8 Jun 2026
- Last updated
- 11 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Single-center, Randomized, Double-blind, Placebo-controlled, Intervention Clinical Trial to Evaluate the Efficacy and Safety of "KoreaGinseng F Max" on Blood Circulation Improvement in Adults With Poor Peripheral Blood Flow
- ClinicalTrials.gov ID
- NCT07643532
- Acronym / sponsor ID
- NIHHS-24-01
- Keywords
- White ginseng extract, KoreaGinseng F Max, Platelet aggregation, Blood circulation, Antiplatelet, Dietary supplement, Functional food
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Haiphong University of Medicine and PharmacyUniversity, hospital or other
- Study start
- 10 Jun 2026 (estimated)
- Primary completion
- 10 Dec 2026 (estimated)
- Study completion
- 10 Jun 2028 (estimated)
- First posted
- 11 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a single-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a white ginseng extract (KoreaGinseng F Max) for improving blood circulation in adults with poor peripheral blood flow.
A total of 100 adults aged 20 to under 65 years with platelet aggregation above 55% will be enrolled and randomly assigned in a 1:1 ratio to receive either the white ginseng extract or a matching placebo for 8 weeks. Each participant takes 3 tablets after breakfast and 3 tablets after dinner (6 tablets per day).
The main goal is to measure the change in ADP-induced platelet aggregation from baseline (Visit 2) to the end of treatment (Visit 4, Week 8). The study also assesses effects on coagulation measures, blood lipids, serotonin, blood pressure, white blood cell count, and overall safety.
Detailed description
Study design: Single-center, randomized, double-blind, placebo-controlled, parallel-group interventional trial.
Population: Men or women aged ≥20 and <65 years requiring improvement of blood circulation, with ADP- and collagen-induced platelet aggregation above 55%, who provide written informed consent.
Intervention: Participants are randomized 1:1 to the test product (white ginseng extract, KoreaGinseng F Max) or a matching placebo control. Dosing is 3 tablets after breakfast and 3 tablets after dinner (6 tablets/day) for 8 weeks, taken orally.
Visit schedule: Screening (Visit 1, Week -2 to 0); randomization/baseline (Visit 2, Week 0); interim visit (Visit 3, Week 4 ±5 days); end-of-treatment (Visit 4, Week 8 ±5 days); plus a supplementary visit if needed.
Primary endpoint: Change in ADP-induced platelet aggregation from baseline (Visit 2) to Visit 4.
Secondary endpoints: Percent change in ADP-induced platelet aggregation; change and percent change in prothrombin time and activated partial thromboplastin time; change in serum lipids (total cholesterol, HDL-C, LDL-C, triglycerides); change in serotonin; change in systolic and diastolic blood pressure; and - all from baseline to Visit 4.
Sample size: 100 participants (2 groups); approximately 50 evaluable per group, accounting for an ~8% dropout rate.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Two parallel groups randomized 1:1 to white ginseng extract or matching placebo.
| Arm | Type | Receives |
|---|---|---|
| White Ginseng Extract (KoreaGinseng F Max) | Experimental | Dietary Supplement: KoreaGinseng F MaxParticipants receive white ginseng extract (KoreaGinseng F Max), 3 tablets after breakfast and 3 tablets after dinner (6 tablets/day) orally for 8 weeks. |
| placebo | Placebo comparator | Dietary Supplement: PlaceboParticipants receive a matching placebo control product on the same dosing schedule (3 tablets after breakfast and 3 tablets after dinner, 6 tablets/day) orally for 8 weeks. |
Who may qualify
- Ages
- 20 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Men or women aged 20 to under 65 years
- Platelet aggregation response above 55% (satisfied for both collagen and ADP)
- Provides voluntary written informed consent to participate
Key exclusion criteria (21 listed)
- History of hypersensitivity or allergy to ginseng-containing products that may affect the results
- Surgery under general anesthesia within 12 weeks before participation
- Use of contraindicated products such as red ginseng or omega-3 fatty acids within 2 weeks before screening
- Use of antiplatelet drugs such as aspirin within 2 weeks before screening (subjects on prophylactic aspirin <100 mg with unchanged dose/method may participate)
- Uncontrolled hypertension not managed by medication (systolic BP >160 mmHg or diastolic BP >97 mmHg)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| KoreaGinseng F MaxWhite ginseng extract; 3 tablets after breakfast and 3 tablets after dinner (6 tablets/day), oral, for 8 weeks. | Dietary supplement | White Ginseng Extract (KoreaGinseng F Max) |
| PlaceboMatching placebo control product; same dosing schedule and duration as the test product. | Dietary supplement | placebo |
Primary outcome
Change in ADP-induced platelet aggregation
Time frame: Baseline (Visit 2) and Week 8 (Visit 4)
Change in adenosine diphosphate (ADP)-induced platelet aggregation from baseline to end of treatment.
6 secondary outcomes
Percent change in ADP-induced platelet aggregation
Time frame: Baseline (Visit 2) and Week 8 (Visit 4)
Change and percent change in prothrombin time (PT)
Time frame: Baseline (Visit 2) and Week 8 (Visit 4)
Change and percent change in activated partial thromboplastin time (aPTT)
Time frame: Baseline (Visit 2) and Week 8 (Visit 4)
Change and percent change in serum lipids (total cholesterol, HDL-C, LDL-C, triglycerides)
Time frame: Baseline (Visit 2) and Week 8 (Visit 4)
Change and percent change in serum serotonin
Time frame: Baseline (Visit 2) and Week 8 (Visit 4)
Change and percent change in blood pressure (systolic and diastolic)
Time frame: Baseline (Visit 2) and Week 8 (Visit 4)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Blood Circulation
Not yet recruitingObservational study
Risk Factors for Spinal Cord Injury After Minimally Invasive Aortic Repair
Spinal Cord Ischemia
Not yet recruitingObservational study
Relationship Between Frontal QRS-T Angle and Collateral Circulation in Coronary Artery Chronic Total Occlusion
Chronic Total Occlusion (CTO), Frontal QRS-T Angle
Recruiting
Transspinal Stimulation With and Without Blood Flow Restricted Exercise Via Telehealth in Persons With Tetraplegia
Tetraplegia/Tetraparesis
Active, not recruitingObservational study
Effects of Transitional Circulation in ELBW Infants
Neonatal Prematurity, Hypotension
Not yet recruiting
Effects of Low-Load Blood Flow Restriction Resistance Training With and Without Hip Abductor Strengthening in Patients With Knee Osteoarthritis.(BFR)
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing KoreaGinseng F Max in people with Blood Circulation and Peripheral Blood Flow, run by Haiphong University of Medicine and Pharmacy at 1 site in Vietnam.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 11 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Vietnam. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in ADP-induced platelet aggregation (time frame: Baseline (Visit 2) and Week 8 (Visit 4)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2026.